Table 3.
Predictors of Overall Survival in all patients with isolated Breast cancer liver metastases (n=167)
| Variable | Category | No. of patients | Median survival (95%CI) | p | Multivariate analysis OR (95%CI); p-value |
|---|---|---|---|---|---|
| Demographics | |||||
| Age at BCLM, years | < 50 ≥ 50 |
68 99 |
46(36-56) 41(20-62) |
0.5 | NA |
| Breast Cancer | |||||
| Primary tumor, T | T1 T2 T3 T4 |
53(43%) 59(48%) 8(7%) 2(2%) |
58(38-78) 43(31-55) 31(12-51) 25(24-NR) |
0.2 | NA |
| Nodal | Negative Positive |
66(46%) 78(54%) |
46(28-64) 40(31-49) |
0.02 | 2 (1.1-3.3); 0.01 |
| Tumor grade/ differentiation | Grade 1 Grade 2 Grade 3 |
0 32(24%) 104(76%) |
0 58(38-77) 45(27-62) |
0.7 | NA |
| American Joint Committee on Cancer (AJCC) staging (7th edition) | 1 2 3 4 |
24(19%) 38(31%) 28(23%) 33(27%) |
34(30-38 50(28-71) 26(10-41) NR |
0.07 | NA |
| Estrogen Receptor(ER) status | Negative Positive |
50(34%) 97(66%) |
58(32-83) 50(33-66) |
0.8 | NA |
| Progesterone Receptor(PR) status | Negative Positive |
69(47%) 78(53%) |
43(16-71) 58(31-86) |
0.1 | NA |
| Human epidermal growth factor receptor 2 (HER2) status | Negative Positive |
78(62%) 47(38%) |
40(32-49) 60(47-72) |
0.04 | NA |
| Adjuvant chemotherapy after breast surgery | Without With |
38(29%) 91(71%) |
33(16-50) 43(28-59) |
0.2 | NA |
| Adjuvant hormonal therapy after breast surgery | Without With |
59(44%) 74(56%) |
40(31-49) 46(26-66) |
0.7 | NA |
| Adjuvant radiotherapy after breast surgery | Without With |
55(40%) 81(60%) |
46(25-67) 42(27-56) |
0.6 | NA |
| Trastuzumab (Herceptin) treatment | No Yes |
126(75%) 41(25%) |
40(33-47) 69(52-86) |
0.04 | 0.5 (0.3-0.9); 0.02 |
| Liver metastases | |||||
| Number | Solitary Multiple |
73(44%) 92(56%) |
50(22-77) 41(31-52) |
0.02 | 1.2 (1.06-1.4); 0.006 |
| Site of BCLM | Unilobar Bilobar |
95(59%) 67(41%) |
58(39-77) 34(22-46) |
0.01 | 1.04 (0.6-2); 0.9 |
| Largest size | <5 cm ≥ 5cm |
128(78%) 36(22%) |
45(30-60) 36(5-69) |
0.8 | NA |
| Cumulative size | <5 cm ≥ 5cm |
93(57%) 69(43%) |
50(32-67) 36(25-47) |
0.07 | 1.3 (0.7-2.2); 0.4 |
| Presentation of BCLM | Synchronous Metachronous |
35(21%) 132(79%) |
NR 42(30-53) |
0.1 | NA |
| Time interval of breast cancer diagnosis to BCLM diagnosis | <5 years ≥ 5 years |
100(70%) 42(30%) |
42(34-49) 58(30-87) |
0.1 | NA |
Continuous variables are reported as median (IQR) and continuous variables as number; BCLM: Breast cancer liver metastasis; CI: Confidence interval; OR: Odds ratio; NR - not reached.